Expert Pitch

Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE Trial

6-Oct-2017 3:05 PM EDT, by Yale Cancer Center/Smilow Cancer Hospital contact patient services

Credit: JNCCN

Daniel P. Petrylak, MD, of Yale Cancer Center, discusses phase III study findings on docetaxel with or without ramucirumab in platinum-refractory advanced or metastatic urothelial carcinoma.

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program

Contact: [email protected] or (203) 737-8076

MEDIA CONTACT

0.09273

Expert Pitch

Expert Query

Expert Directory

Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE Trial

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program

MEDIA CONTACT

TYPE OF ARTICLE

SECTION

CHANNELS

KEYWORDS